Tags : High

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III

Shots: The P-III EVOLVE-1 and EVOLVE-2 studies result involves assessing of Emgality (galcanezumab-gnlm, 120mg & 240mg) vs PBO in 1,700 patients with low (4 to<8 monthly migraine headache days) and high (8-14 monthly migraine headache days) frequency episodic migraine The collective studies result demonstrated improvement in both subgroups with mean % of patients with ≥50%, […]Read More